The post Death Cross Appears on Bitcoin Charts as Historical Pattern Shows 50% Crash Risk ⋆ ZyCrypto appeared on BitcoinEthereumNews.com. Advertisement &nbsp &The post Death Cross Appears on Bitcoin Charts as Historical Pattern Shows 50% Crash Risk ⋆ ZyCrypto appeared on BitcoinEthereumNews.com. Advertisement &nbsp &

Death Cross Appears on Bitcoin Charts as Historical Pattern Shows 50% Crash Risk ⋆ ZyCrypto

For feedback or concerns regarding this content, please contact us at [email protected]
Advertisement

Bitcoin (BTC) showed limited price movement on Wednesday before slipping overnight into Friday amid a surge in selling pressure.

Notably, by early February 28, BTC had declined further to around $63,000–$64,000, driven by heavy selling and liquidations following military strikes involving Israel and Iran. Over the past 2 weeks, the world’s largest cryptocurrency has fallen nearly 7%, reflecting heightened market uncertainty.

Notably, amid this drop, the market remains cautious, with some analysts warning that prices could fall further.

In a note on X, popular analyst Ali Charts noted that after Bitcoin peaked in December 2017, the cryptocurrency underwent a sharp correction of roughly 67%.

The 3-day death cross appeared in November 2018,” he said. 

Advertisement
 

Following that, BTC experienced another steep 50% drop, marking what many consider the final capitulation phase of that bear market.

According to the pundit, the death cross, which occurs when a shorter-term moving average crosses below a longer-term moving average, has historically signaled sustained downside pressure in Bitcoin’s cyclical trends and occurred this week.

Furthermore, blockchain analytics firm Glassnode observed that profit-taking activity at high price levels could suppress upward momentum. In a tweet on Wednesday, the firm noted that when the smoothed Net Realized P&L exceeded $5 million per hour, Bitcoin’s price stalled at around $69,400.

Profit-taking continues to absorb momentum at the $70k threshold, consistent with a thin liquidity regime,” he explained. 

This suggests that even relatively modest selling can significantly affect price recovery in current market conditions, underscoring the challenges of maintaining upward momentum at critical resistance levels.

Elsewhere, according to analyst Willy Woo, Bitcoin’s bearish trend may persist through 2026. Woo warned that depleted liquidity in spot and futures markets could keep BTC near $45,000, with severe crises potentially pushing support to $30,000 and $10,000 as a last line of defense. CryptoQuant agrees, forecasting the cycle bottom between September and December 2026, with bullish momentum unlikely until early 2027.

However, despite these warnings, some analysts remain more optimistic. Analyst The Great Mattsby pointed to Fibonacci retracement levels as evidence that Bitcoin is not entering a macro bear market.

His analysis noted that the 1.618 Fibonacci extension from the 2017 high and low, which coincided with Bitcoin’s market top in 2021 at approximately $62,000, has recently been revisited as support.

This backtest provides evidence that long-term bullish structures remain intact,” he argued. 

Such technical levels are often used by traders to identify potential floors and ceilings for price action, indicating that while short-term volatility may be high, the broader trend could still be constructive.

At press time, BTC was trading at $72,611, up 1.30% over the past 24 hours.

Source: https://zycrypto.com/death-cross-appears-on-bitcoin-charts-as-historical-pattern-shows-50-crash-risk/

Market Opportunity
CROSS Logo
CROSS Price(CROSS)
$0.06716
$0.06716$0.06716
-13.66%
USD
CROSS (CROSS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09